Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

  • Gemma Bruera1,
  • Katia Cannita1,
  • Daniela Di Giacomo2,
  • Aude Lamy3,
  • Giancarlo Troncone4,
  • Antonella Dal Mas5,
  • Gino Coletti5,
  • Thierry Frébourg6,
  • Jean Christophe Sabourin7,
  • Mario Tosi6,
  • Corrado Ficorella1 and
  • Enrico Ricevuto1Email author
BMC Medicine201210:135

DOI: 10.1186/1741-7015-10-135

Received: 21 April 2012

Accepted: 8 November 2012

Published: 8 November 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
21 Apr 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Author responded Author comments
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
8 Nov 2012 Editorially accepted
8 Nov 2012 Article published 10.1186/1741-7015-10-135

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Medical Oncology, S. Salvatore Hospital, University of L'Aquila
(2)
Department of Experimental Medicine, University of L'Aquila
(3)
Laboratory of Tumor Genetics, University Hospital
(4)
Department of Biomorphologic and Functional Sciences, University Federico II
(5)
Pathology Department, S. Salvatore Hospital
(6)
INSERM U614, University of Rouen
(7)
Department of Pathology, INSERM U614, Rouen University Hospital

Advertisement